Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05962424

HNC: Human Neural Circuits Electrophysiology During Cognition

The purpose of this study is to understand how ketamine brings about dissociative symptoms.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Psychiatric Disorder Mental Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Stanford University

Palo Alto, California, 94306, United States

Location status: Recruiting

Location contact

Kishandra Patron, BS

CONTACT

About this study

The goal of this proposed research is to record the effects of ketamine on brain activity to understand the changes that occur during antidepressant therapy and the side effect of dissociation. This research is designed to probe altered cognitive states associated with dissociation, depression, and other neuropsychiatric conditions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient in clinical neuro inpatient units at Stanford Medical Center
  • Age >18 years old
  • Female participants are expected to use an effective method of birth control throughout the study which includes: hormonal methods (birth control pills, patches, injections, vaginal ring or implants), barrier methods (condom or diaphragm) used with spermicide, intrauterine device (IUD), or abstinence (no sex)

Exclusion criteria

  • Lifetime psychotic disorder
  • Pregnant or nursing females
  • Prior adverse ketamine response
  • Use of ketamine in past 7 days

Treatment and study plan

Ketamine Hydrochloride

Drug

Ketamine is an FDA-approved dissociative anesthetic.

Other names: Ketalar

Primary outcomes

  1. Number of participants with dissociative events during ketamine infusion as assessed by CADSS (Clinician-Administered Dissociative State Scale)

    Time frame: up to 1 week

    The CADSS is an instrument for the measurement of dissociative symptoms. The CADSS comprises 23 subjective items and participant's responses are coded on a 5-point scale (0 = Not at all; 4 = Extreme). The higher the number on the CADSS, the more severe the symptoms.

Study contacts

Contact information is provided by the study sponsor or research team.

Arjay Cordero

CONTACT

[email protected]

650-580-9000

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Important dates

Study start
2023
Primary completion
2030
Study completion
2030
First posted
Jul 27, 2023
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.